Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Global Forecast 2024-2030

Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Global Forecast 2024-2030

The Biomanufacturing Viral Detection & Quantification Market size was estimated at USD 2.67 billion in 2023 and expected to reach USD 2.89 billion in 2024, at a CAGR 8.40% to reach USD 4.71 billion by 2030.

The biomanufacturing viral detection and quantification market encompasses the industries and sectors involved in developing, producing, and commercializing technologies, services, and solutions for identifying and measuring viral contaminants in the biomanufacturing process. The increased investments in biopharmaceutical R&D is contributing to the market growth. The heightened awareness of product safety following high-profile contamination cases and the introduction of stringent regulatory requirements drive the business growth in the biomanufacturing viral detection & quantification market. However, the high costs of testing and the complexity of regulatory approval processes may create barriers to entry for smaller companies, affecting market competitiveness. The need for highly skilled individuals to perform and interpret complex assays adds to market space operational challenges. Moreover, developing novel viral inactivation methods and real-time viral detection technologies creates innovative opportunities in the market. The research initiative, which is directed towards standardizing assays across different platforms, creates significant growth potential in the market.

Regional Insights

In the Americas, the United States and Canada are pivotal markets for biomanufacturing viral detection and quantification. These Americas region is characterized by advanced healthcare systems, high per capita healthcare spending, and stringent regulatory environments that govern the safety and efficacy of biologics. In the European countries, the biomanufacturing sector is advanced with a strong emphasis on innovation, quality, and safety. Customers in this EMEA region are keen on adopting state-of-the-art viral detection technologies that align with the stringent EU regulatory frameworks. The Middle East shows promising growth with increased healthcare investments and a rising demand for biopharmaceuticals. The market for viral detection and quantification in the Middle East region is nascent, with a growing consumer need for quality assurance in locally produced and imported biologics. The Asia Pacific region is experiencing surge in the biomanufacturing domain, due to robust economic growth, increasing healthcare expenditures, and growing technological adoption. The demand for viral detection and quantification solutions is driven by the burgeoning vaccine production sector and export market in the APAC region, with customers showing a preference for cost-effective yet reliable technologies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Biomanufacturing Viral Detection & Quantification Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing incidence of viral diseases and need for enhanced detection techniques
• Exponential investments in drug development and manufacturing processes
• Growing demand for portable and point-of-care vital testing

Market Restraints

• Lack of skilled personnel and high cost of quantification devices

Market Opportunities

• Rapid advancements in viral testing and quantification methods
• Emphasis on environmental monitoring of viral contaminants

Market Challenges

• Technical difficulties associated with the isolation of viral load

Market Segmentation Analysis

• Offering Type: Advances in consumables for high accuracy
• Technology: Improved adoption of PCR technique for high specificity
• Application: Surging applications in vaccines & therapeutics manufacturing
• End User: Rising adoption from CROs and CDMOs for viral quantification

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biomanufacturing Viral Detection & Quantification Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biomanufacturing Viral Detection & Quantification Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Launch of DNAllergen Real-time PCR Kits for the Reliable Detection Of Target Allergen Sequences

Gold Standard Diagnostics has launched the DNAllergen real-time PCR kits, the latest advancement in allergen testing technology. Gold Standard Diagnostics kits have been expertly designed to elevate both the specificity and sensitivity of allergen detection, offering an exceptional value for laboratories in viral detection.

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Virax Biolabs Group Limited has announced a significant distribution agreement to deploy its state-of-the-art Avian Influenza A Virus real-time PCR test kit across European markets adhering to CE marking standards. This crucial differentiation tool rapidly identifies AIV infections and discerns between various subtypes, notably the pathogenic H5, H7, and H9 strains, including the emergent H5N1, directly addressing the growing surveillance needs amid the H5N1's spread in Europe. Designed for laboratory application, this kit epitomizes an essential step in preemptively screening at-risk populations and individuals in contact with affected avian populations.

New BGI Genomics Fluorescent RT-PCR Kit Approved for COVID-19, Influenza A & B Detection in Australia

BGI Genomics announced a significant advancement in the domain of viral detection by securing entry to the Australian Register of Therapeutic Goods for its innovative Multiplex Real-time Fluorescent RT-PCR Kit. This state-of-the-art diagnostic tool markedly enhances the efficiency of biomanufacturing viral detection procedures by enabling qualitative, in vitro differentiation of SARS-CoV-2, influenza A, and influenza B viruses, via a single sampling of throat swabs. With this approval, the company aimed to expand their business presence in the Australia region.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biomanufacturing Viral Detection & Quantification Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biomanufacturing Viral Detection & Quantification Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BASF SE, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Charles River Laboratories, Danaher Corporation, Genscript Biotech Corporation, Hamilton Company, Illumina, Inc., LG Chem, Ltd., Lonza Group Ltd., Merck KGaA, New England Biolabs, Norgen Biotek Corp., Oxford Nanopore Technologies PLC, PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Recipharm AB, Sartorius AG, Shimadzu Corporation, Takara Bio Inc., Thermo Fisher Scientific Inc., Thomas Scientific LLC, and Zymo Research Corporation.

Market Segmentation & Coverage

This research report categorizes the Biomanufacturing Viral Detection & Quantification Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering Type
• Consumables
• Accessories
• Kits & Assays
• Instruments
• Services
• Technology
• Enzyme-Linked Immunosorbent Assay
• Flow Cytometry
• Plaque Assay
• Polymerase Chain Reaction
• Application
• Blood & Blood Products Manufacturing
• Cellular & Gene Therapy Products Manufacturing
• Stem Cell Products Manufacturing
• Tissue & Tissue Products Manufacturing
• Vaccines & Therapeutics Manufacturing
• End User
• CROs & CDMOs
• Life Science Companies
• Testing Laboratories

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year